Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 9,142 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: Alisertib, Fulvestrant, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Delavirdine mesylate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 45
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more

Conditions: Breast Carcinoma
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Lymphoproliferative Disorder
Interventions: rituximab, cyclophosphamide, methylprednisolone, prednisone; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: B-cell Non-Hodgkin Lymphoma
Interventions: Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 12 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sulindac, pharmacological study; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pleuropulmonary Blastoma
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Dexrazoxane, Doxorubicin, Echocardiography Test, Ifosfamide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Positron Emission Tomography, Topotecan, Ultrasound Imaging, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 80
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more

Conditions: Malignant Glioma
Interventions: Diffusion Weighted Imaging, Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Temozolomide; Procedure · Drug · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiac Disease
Interventions: GE Attenuation Corrected Hawkeye Camera; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer, Squamous Lung Dysplasia, Tobacco Use Disorder
Interventions: deuterated phenanthrene tetraol, pharmacological study, laboratory biomarker analysis; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Rochester, Minnesota • Buffalo, New York

Conditions: Multiple Sclerosis
Interventions: NAbs testing; Procedure
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 49
States / cities: Phoenix, Arizona • Berkley, California • Fresno, California + 43 more

Conditions: Obese Adults
Interventions: Placebo, Tirzepatide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Endoscopic Ultrasound
Interventions: High flow nasal cannula; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ventricular Tachycardia, Arrythmia, Heart Diseases, Cardiovascular Diseases
Interventions: Saline Enhanced Radiofrequency (SERF) ablation; Device
Lead sponsor: Thermedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Maywood, Illinois • Rochester, Minnesota • Nashville, Tennessee

Conditions: Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma
Interventions: Best Practice, Biospecimen Collection, Dietary Intervention, Glucose Measurement, Magnetic Resonance Imaging, Monitoring, Questionnaire Administration, Supportive Care; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Interventions: Surgery, Preoperative chemotherapy; Procedure · Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 92 more

Conditions: Breast Carcinoma
Interventions: Electronic Health Record Review, Questionnaire Administration, Survey Administration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 23
States / cities: Albert Lea, Minnesota • Baxter, Minnesota • Bemidji, Minnesota + 19 more

Conditions: Multiple Myeloma
Interventions: Cevostamab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Aurora, Colorado • Jacksonville, Florida • Baltimore, Maryland + 5 more

Conditions: Vasomotor Symptoms, Menopausal Symptoms
Interventions: Estetrol oral tablet, Placebo oral tablet; Drug
Lead sponsor: Estetra; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,015 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 111
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 82 more

Conditions: Heart Failure
Interventions: Pacing Lead; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 20
States / cities: Long Beach, California • Palo Alto, California • Newark, Delaware + 17 more

Conditions: Chronic Hepatitis C Virus Infection
Interventions: CTS-1027, Placebo; Drug · Other
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 15 more

Conditions: Endothelial Dysfunction
Interventions: darapladib, placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
Interventions: Osteoporosis Choice Decision Aid; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Myelodysplastic Syndrome
Interventions: MEDI4736 Evaluate MEDI4736 in MDS, VIDAZA, tremelimumab; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 16
States / cities: Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 12 more

Search by objective public record fields.

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy

Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System

Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy

Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity

High Flow Nasal Cannula Compared to Standard Oxygen for Endoscopic Ultrasound

SERF VT Ablation Early Feasibility Study (EFS)

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

Attain StarFix™ Model 4195 Left Ventricular Lead

Study of CTS-1027 in Hepatitis C Patients

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome